Comparative Pharmacology
Head-to-head clinical analysis: DIFLUCAN versus MYHIBBIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFLUCAN versus MYHIBBIN.
DIFLUCAN vs MYHIBBIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diflucan (fluconazole) is a triazole antifungal agent that inhibits fungal cytochrome P450 14-alpha-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability and inhibition of fungal growth.
Myhibbin is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH), thereby blocking the de novo synthesis of guanosine nucleotides. This inhibits T- and B-lymphocyte proliferation and antibody production.
Oral or IV: 200-400 mg loading dose, then 100-200 mg once daily. Dose and duration depend on indication.
MYHIBBIN is not a recognized FDA-approved drug. No standard dosing information is available.
None Documented
None Documented
30 hours (range 20-50 hours); prolonged in renal impairment (up to 98 hours in CrCl <20 mL/min)
Terminal half-life: 12-15 hours in adults; prolonged in renal impairment (up to 30 hours)
Renal: 80% unchanged; fecal/biliary: 11% as metabolites
Renal excretion as unchanged drug (70-80%), biliary/fecal (15-20%)
Category C
Category C
Antifungal
Antifungal